China Regenerative Medicine International Limited
中國再生醫學國際有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8158)

SUPPLEMENTAL ANNOUNCEMENT TO ANNUAL RESULTS ANNOUNCEMENT AND THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2018

Reference is made to the announcements (the "**Announcements**") of China Regenerative Medicine International Limited (the "**Company**" together with its subsidiaries, the "**Group**") dated 12 April 2019 and dated 29 May 2019, and the annual report ("**Annual Report**") of the Company for the year ended 31 December 2018. Terms used herein shall have the same meanings as defined in the Announcements and the Annual Report unless the context requires otherwise. In addition to the information provided in the Announcements and the Annual Report, the Board wishes to provide further information in relation to note 20 "Financial Assets At Fair Value Through Other Comprehensive Income" and to note 23 "Financial Assets At Fair Value Through Profit or Loss" to the Annual Report in this supplemental announcement ("**Supplemental Announcement**").

1. NOTE 20 "FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME"

Further particulars are as follows:

Name of Company	Share type	At 31/12/2018 Fair value *HK$'000*	Shareholdings held *%*	Investment costs *HK$'000*	Principal business	Size to total assets *%*
中新（黑龍江）互聯網小額貸款有限公司	Unlisted	161,445	2%	112,928	Online lending service	11.3%

During the year ended 31 December 2018, the Group did not receive dividend. At 31 December 2018, 中新（黑龍江）互聯網小額貸款有限公司 with its registered capital of RMB5,000 million was one of the top 10 in terms of registered capital base of online lenders in the PRC according to 2018 publication of The People's Bank of China. The Board believes that the implementation of various regulatory measures will lead to healthy growth of the online lending industry in the PRC and will be beneficial to players with stronger capital base. The Board continues to view this as a sound and long term investment.

2. NOTE 23 "FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS"

Further particulars are as follows:

Name of fund	Fund type	At 31/12/2018 Fair value *HK$'000*	Shareholdings held *%*	Investment costs *HK$'000*	Principal business	Size to total assets *%*
Haitong Internatioal ZhongHua Finance. Acquisition Fund I, L.P. (the "**Fund**")	Unlisted	298,296	N/A	273,348	Private equity fund	21.0%

During the year ended 31 December 2018, the Group did not receive dividend from the Fund. As explained in the announcement of the Company dated 17 July 2017, the Fund principally invested in companies in the skin care and medical products industries. The Board remains positive on the outlook of skin care and medical products industries.

Save as disclosed in this Supplemental Announcement, the above supplemental information does not affect other information contained in the Announcements and the Annual Report.

By Order of the Board
China Regenerative Medicine International Limited
Ray Yip
Chairman and Executive Director

Hong Kong, 8 October 2019

As at the date of this announcement, the executive Directors are Dr. Ray Yip (Chairman) and Mr. Wang Xuejun (Chief Executive Officer); the non-executive Director is Dr. Zhang Bin and the independent non-executive Director is Dr. Fang Jun.